Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

Cited by papers we hold 13

• Unveiling the mechanisms and challenges of cancer drug resistance · 2024
  No notice
• Epigenetics-targeted drugs: current paradigms and future challenges · 2024
  No notice
• Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities · 2022
  No notice
• Targeting fibrosis: mechanisms and clinical trials · 2022
  No notice
• Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy · 2021
  No notice
• Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents · 2021
  No notice
• Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review · 2021
  No notice
• Wnt/β-catenin signaling in cancers and targeted therapies · 2021
  No notice
• Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives · 2020
  No notice
• Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials · 2020
  No notice
• Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer · 2020
  No notice
• TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019 · 2019
  No notice
• Wnt/β-Catenin Signaling in Liver Cancers · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.